cGMP Signaling, Phosphodiesterases and Major Depressive Disorder

Author(s): Gillian W. Reierson, Shuyu Guo, Claudio Mastronardi, Julio Licinio, Ma-Li Wong.

Journal Name:Current Neuropharmacology

Volume 9 , Issue 4 , 2011

Abstract:

Deficits in neuroplasticity are hypothesized to underlie the pathophysiology of major depressive disorder (MDD): the effectiveness of antidepressants is thought to be related to the normalization of disrupted synaptic transmission and neurogenesis. The cyclic adenosine monophosphate (cAMP) signaling cascade has received considerable attention for its role in neuroplasticity and MDD. However components of a closely related pathway, the cyclic guanosine monophosphate (cGMP) have been studied with much lower intensity, even though this signaling transduction cascade is also expressed in the brain and the activity of this pathway has been implicated in learning and memory processes. Cyclic GMP acts as a second messenger; it amplifies signals received at postsynaptic receptors and activates downstream effector molecules resulting in gene expression changes and neuronal responses. Phosphodiesterase (PDE) enzymes degrade cGMP into 5GMP and therefore they are involved in the regulation of intracellular levels of cGMP. Here we review a growing body of evidence suggesting that the cGMP signaling cascade warrants further investigation for its involvement in MDD and antidepressant action.

Keywords: Major Depression, cyclic guanosine, monophosphate, neuroplasticity, phophodiesterases, cyclases, antidepressants, pharmacology, neurogenesis, Major depressive disorder (MDD), cyclic guanosine monophosphate

Rights & PermissionsPrintExport

Article Details

VOLUME: 9
ISSUE: 4
Year: 2011
Page: [715 - 727]
Pages: 13
DOI: 10.2174/157015911798376271

Article Metrics

PDF: 31
HTML: 0
EPUB: 0
PRC: 0